Choose a language
March, 01 2016
The Group, specializing in glass pharmaceutical primary packaging, glass converting machines and visual inspection systems for the pharmaceutical industry, registered revenues for 337,1 million Euros in 2015, with an increase of 16,8% from 2014 and 87,1 million Euros EBITDA (25,8% on revenues).
Stevanato Group, specializing in glass pharmaceutical primary packaging, glass converting machines and visual inspection systems for the pharmaceutical industry, continues its double digit growth.
The Group approved pre-closing data of the FY2015 registering a consolidated revenue of 337,1 million Euros, an increase of 16,8% compared to the 288,5 million Euros of 2014. The good performance is the result of both business areas, Pharmaceutical Systems e Engineering Systems.
The 2015 EBITDA reaches 87,1 million Euros (73,5 million Euros in 2014), with an incidence on revenues of 25,8%. EBIT is 59,4 million Euros (17,6% of revenues), compared to the 51,2 million Euros of 2014.
On December 31st, 2015, the Net Financial Position was negative for 80,7 million Euros (in 2014 it was negative for 62,9 million Euros). Debt – with a Net Debt/Ebitda Ratio of 0,9 - is in line with the Industrial Plan. The increase is due to the completion of InnoScan acquisition and the first investments for the Brazilian plant in Sete Lagoas, Minas Gerais.
In 2015 Stevanato Group registered a net profit of 35,6 million Euros (compared to 29,4 million in 2014).
“The 2015 growth reflects our development projects aimed at maintaining the trend for the future - states Franco Stevanato, CEO of Stevanato Group. – In order to continue growing in the value chain we developed a long term Vision based on three main pillars.
We developed an internationalization strategy in order to supply the markets locally. The new production plant in Brazil is fully in line with this strategy. The groundbreaking ceremony was held last 4th February and it will be operative starting from 2017.
Moreover, we are always committed to research in terms of treatments, materials, processes, device ideation in order to guarantee our products a competitive advantage and to add value to our core business, making the product more and more innovative every time.
We also activated an acquisition process to move to the higher part of the value chain towards a fully integrated system. In the future Stevanato Group will not just offer the glass pharmaceutical container, but an integrated system for injectables. This is the main goal”.
With the aim to grow by acquisitions, at the beginning of 2016 the Group acquired the Danish SVM Automatik, specialized in assembly, packaging machines and serialization solution.